Atreca, Inc., a biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. More Details
Flawless balance sheet and overvalued.
Share Price & News
How has Atreca's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: BCEL has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: BCEL exceeded the US Biotechs industry which returned 32.5% over the past year.
Return vs Market: BCEL exceeded the US Market which returned 17.8% over the past year.
Price Volatility Vs. Market
How volatile is Atreca's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StRead This Before Selling Atreca, Inc. (NASDAQ:BCEL) Shares
2 months ago | Simply Wall StHere's What Atreca, Inc.'s (NASDAQ:BCEL) Shareholder Ownership Structure Looks Like
3 months ago | Simply Wall StHow Much Are Atreca, Inc. (NASDAQ:BCEL) Insiders Spending On Buying Shares?
Is Atreca undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate BCEL's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate BCEL's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: BCEL is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: BCEL is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate BCEL's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: BCEL is good value based on its PB Ratio (2.7x) compared to the US Biotechs industry average (3.4x).
How is Atreca forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BCEL is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: BCEL is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: BCEL is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if BCEL's revenue is forecast to grow faster than the US market.
High Growth Revenue: Insufficient data to determine if BCEL's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if BCEL's Return on Equity is forecast to be high in 3 years time
How has Atreca performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: BCEL is currently unprofitable.
Growing Profit Margin: BCEL is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if BCEL's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare BCEL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BCEL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-7.1%).
Return on Equity
High ROE: BCEL has a negative Return on Equity (-49.56%), as it is currently unprofitable.
How is Atreca's financial position?
Financial Position Analysis
Short Term Liabilities: BCEL's short term assets ($148.6M) exceed its short term liabilities ($7.4M).
Long Term Liabilities: BCEL's short term assets ($148.6M) exceed its long term liabilities ($3.1M).
Debt to Equity History and Analysis
Debt Level: BCEL is debt free.
Reducing Debt: BCEL has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: BCEL has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: BCEL has sufficient cash runway for 1.5 years if free cash flow continues to reduce at historical rates of 37.9% each year.
What is Atreca current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate BCEL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate BCEL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if BCEL's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BCEL's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of BCEL's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
John Orwin (55 yo)
Mr. John A. Orwin has been President, Chief Executive Officer and Director at Atreca, Inc. since April 19, 2018 Mr. Orwin has been a Director of Relypsa, Inc since June 2013 and Seagen Inc. (formerly known ...
CEO Compensation Analysis
Compensation vs Market: John's total compensation ($USD725.01K) is below average for companies of similar size in the US market ($USD1.93M).
Compensation vs Earnings: John's compensation has been consistent with company performance over the past year.
|Chief Scientific Officer||5.42yrs||US$1.11m||no data|
|Chief Financial Officer||1.67yrs||no data||0% |
|Chief Technologist||no data||no data||no data|
|General Counsel & Corporate Secretary||1.25yrs||no data||no data|
|Senior Vice President of Research||no data||no data||no data|
|Chief Business Officer||1.25yrs||no data||no data|
|Senior Vice President of Clinical Research||0.25yr||no data||no data|
Experienced Management: BCEL's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.
|Independent Chairman of the Board||6.83yrs||US$64.13k||0% |
|Chairman of External Scientific Advisory Board & Technical Advisor||1.17yrs||US$150.00k||0.72% |
|Independent Director||6yrs||US$41.28k||0.27% |
|Director||0.42yr||no data||no data|
|Independent Director||4.42yrs||US$38.87k||0% |
|Board Observer||no data||no data||no data|
|Board Observer||no data||no data||no data|
|Independent Director||1.17yrs||US$383.72k||no data|
Experienced Board: BCEL's board of directors are considered experienced (4.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 28.9%.
Atreca, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Atreca, Inc.
- Ticker: BCEL
- Exchange: NasdaqGS
- Founded: 2010
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$522.787m
- Shares outstanding: 36.03m
- Website: https://www.atreca.com
Number of Employees
- Atreca, Inc.
- 450 East Jamie Court
- South San Francisco
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|BCEL||NasdaqGS (Nasdaq Global Select)||Yes||Class A Common Stock||US||USD||Jun 2019|
|0C1||MUN (Boerse Muenchen)||Yes||Class A Common Stock||DE||EUR||Jun 2019|
|0C1||DB (Deutsche Boerse AG)||Yes||Class A Common Stock||DE||EUR||Jun 2019|
Atreca, Inc., a biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody in c ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/10/26 05:36|
|End of Day Share Price||2020/10/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.